04-Nov-2026 14:36:26
ALEMBIC PHARMACEUTICALS Q2 FY27: REVENUE UP 36% YOY, PAT SURGES 81%, EBITDA JUMPS 78%; US BUSINESS GROWS 77% DRIVEN BY STRONG VOLUMES & NEW LAUNCHES
• Revenue: Increased 36% YoY to ₹2,603 Cr. • EBITDA: Jumped 78% YoY to ₹578 Cr, with margin at 22%. • Net Profit: Surged 81% YoY to ₹335 Cr. • US Business: Revenue grew 77% YoY to ₹1,003 Cr, supported by strong volumes and three new launches. • India Branded Business: Revenue rose 14% YoY to ₹725 Cr, driven by growth across key therapies. • Ex-US Business: Revenue increased 12% YoY to ₹440 Cr. • API Business: Revenue surged 39% YoY to ₹436 Cr. • Animal Health: Recorded 23% growth during the quarter. • Regulatory Approvals: Received one ANDA approval, taking cumulative approvals to 245. • H1 FY27 Performance: Revenue increased 31% YoY to ₹4,753 Cr. • Management Outlook: Expects to sustain growth, supported by US launches, improving India momentum and continued Ex-US and API expansion.
ALEMBIC LIMITED